DOCSLIB.ORG

Modulation of Retinal Dopaminergic Cells by Nitric Oxide. a Protective Effect on NMDA-Induced Retinal Injury

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Modulation of Retinal Dopaminergic Cells by Nitric Oxide. a Protective Effect on NMDA-Induced Retinal Injury in vivo 18: 311-316 (2004) Review Modulation of Retinal Dopaminergic Cells by Nitric Oxide. A Protective Effect on NMDA-induced Retinal Injury YASUSHI KITAOKA1 and TOSHIO KUMAI2 Departments of 1Ophthalmology and 2Pharmacology, St Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan Abstract. Nitric oxide (NO) may play an important role in experimental glaucoma (7). Thus, the involvement of regulating retinal neuronal survival. While the precise impact of elevated vitreal glutamate in glaucoma is not well NO mechanisms on retinal neurons remains to be elucidated, it established. Nonetheless, an understanding of the has been reported that low doses of NO may have a biochemical mechanism by which glutamate regulates neuroprotective effect against N-methyl-D-aspartate (NMDA)- retinal neuronal survival is important in developing induced retinal neurotoxicity. Dopamine has also been therapeutics for protecting retinal neuronal cells at the recognized to have neuroprotective actions. Retinal dopaminergic injured site in several ocular disorders including glaucoma, cells can be detected by the immunohistochemical staining of ischemia (8,9) and optic neuropathy (10,11). tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis. We observed that NMDA dramatically decreased in TH NMDA-induced neurotoxicity immunostaining at the junction between the inner nuclear layer and inner plexiform layer, and that this reduction in The excitotoxic effect of glutamate on the retinal neuronal immunostaining was attenuated by the co-injection of NOC 18, cells has been well demonstrated. Among the several an NO donor. Thus, the current review focused on the NO- glutamate receptors, activation of the N-methyl-D-aspartate dopamine interactions in the retinal neuroprotection. (NMDA) receptor causes the degeneration of retinal neuronal cells (12,13). The overstimulation of NMDA Glaucomatous optic damage is associated with the death of receptors initiates a cascade of events involving necrosis and retinal ganglion cells (RGCs). It has been reported that apoptosis in vitro (14). In an in vivo system, Siliprandi et al. large RGCs may be selectively damaged in glaucoma (1-3), (15) demonstrated that a single intravitreal injection of whereas certain types of glaucoma are associated with NMDA led to a loss of cells in the ganglion cell layer (GCL) elevated glutamate in the vitreous body (4). In addition, a and a reduction in the thickness of the inner plexiform layer chronic low-dose elevation of intravitreal glutamate levels (IPL) in the rat retina. Lam et al. reported that TUNEL- can induce RGC death (5). Furthermore, glutamate causes positive cells appeared in the GCL and inner nuclear layer preferentially larger RGC death (6). Therefore, it has been (INL) following an NMDA intravitreal injection. It has suggested that glutamate may play an important role in recently been reported that the intravitreal injection of glaucoma. However, recent studies have reported that NMDA activates a p53-dependent pathway of death in the vitreal glutamate concentrations were not elevated in RGCs of adult mice (16). The involvement of p53 in monkey eyes with anatomic and functional damage from regulating apoptosis in a variety of neuronal cell types is widely known. Furthermore, Manabe and Lipton (17) suggested that NMDA stimulation leads to both proapoptotic, p38 mitogen-activated protein kinase and Correspondence to: Yasushi Kitaoka, Department of antiapoptotic, phosphatidylinositol-3 kinase-Akt, pathways Ophthalmology, St Marianna University School of Medicine, 2-16- in the retina. Thus, even in vivo, several molecular events, 1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. Tel: 81-44-977-8111, Fax: 81-44-976-0509, e-mail: [email protected] including an apoptotic pathway, may play an important role in NMDA-induced retinal neurotoxicity. With respect to Key Words: Dopaminergic cells, nitric oxide, N-methyl-D-aspartate, another mechanism, NMDA-induced retinal damage is also retina, tyrosine hydroxylase. associated with the activation of nitric oxide synthase 0258-851X/2004 $2.00+.40 311 in vivo 18: 311-316 (2004) Figure 1. Immunohistochemistry for tyrosine hydroxylase (TH) of the rat retina at 5 days following intravitreal injection of phosphate-buffered saline (PBS), 200 nmol N-methyl-D-aspartate (NMDA), or 200 nmol NMDA + 0.5 nmol 1-hydroxy-2-oxo-3,3-bis (2-aminoethyl)-1-triazene (NOC 18). (A) Abundant TH immunostaining was observed in the area between the inner nuclear layer (INL) and the inner plexiform layer (IPL) in the control retina (A, arrowhead). The arrow indicates the dopaminergic cell located in the innermost INL. (B) No immunostaining was observed in the NMDA-treated retina. (C) Some TH immunostaining can be observed in the NMDA-treated retina with the co-injection of NOC 18 (C, arrowheads). Scale bar = 50 Ìm. (NOS), which results in nitric oxide (NO) production (18), ganglion cells may have a postjunctional function in the whereas it was reported that the NMDA receptor effect was dendrites and somas of the retinal ganglion cells and a diminished by L-arginine, a natural substrate of NOS (19). neuromodulator function at the nerve terminals of the retinal In addition, it has been reported that NO can decrease ganglion cells (29). Furthermore, NO produced by NOS in the NMDA receptor activity (20,21). Thus, it is likely that amacrine and ganglion cells may be a paracrine modulator of NMDA and NO may influence each other. cell death within the retinal tissue (30). Localization of NOS in the retina Possible role of NO in the retina NO is generated by the oxidation of L-arginine, a reaction that NO, a free radical gas with a half-life of a few seconds, has is catalyzed by the enzyme NOS (22). Several investigators been shown to play various physiological and reported the expression of NOS in the retina (23-29). NADPH- pathophysiological roles in the nervous system (31). NO has diaphorase staining has been used as a histological marker of been reported to have both neuroprotective (20,32) and NOS (23-27). NOS-expressing neurons were found in both the neurotoxic functions (33,34) in the central nervous system INL and GCL (24) and two types of amacrine cells in the INL (CNS). NO may also play a controversial role in retinal containing NOS have also been distinguished (25,26). In adult neuronal cell death (18,35,36). One possible cause of this rat retina, weakened immunoreactivity of the endothelial NOS role is the redox state of NO (37). Lipton et al. (37) (eNOS) protein was observed in the IPL and the contour of suggested that NO might lead to neurotoxicity when it large cells was stained within the GCL (28). Furthermore, the reacts with superoxide, but it prevents NMDA receptor- immunoreactivity of the neuronal NOS (nNOS) protein in the mediated neurotoxicity when converted to NO+. Another IPL was weakened and the contour of large cells was stained possibility is that this role is due to the different within the GCL (28). nNOS mRNA is present in many cell experimental concentrations of NO. Kashii et al. (18) bodies in the INL and is present in increased amounts in large reported that low concentrations (50 ÌM) of S- cell bodies proximal to the IPL in the retina of rats (29). In the nitrosocysteine (SNOC; an NO-generating agent) or sodium GCL, cells with large somas are positive for nNOS mRNA (29). nitroprusside (SNP; an NO donor) had neuroprotective In human eyes, the nNOS mRNA and nNOS proteins were effects on retinal neurons against NMDA-induced also present in the INL and GCL (29). The NOS in retinal neurotoxicity. However, high concentrations (500 ÌM) of 312 Kitaoka and Kumai: Modulation of Retinal Dopaminergic Cells by NO SNOC or SNP alone both caused a reduction in cell region (43,44). Pilz et al. (45) demonstrated that cGMP and viability. Furthermore, Kashiwagi et al. (35) reported that NO activate JunB, c-Jun, JunD and c-Fos mRNA NO has a dual action on retinal RGC survival. At ≥ 100 transcriptions. JunB, c-Jun, JunD and c-Fos comprise the ÌM, S-nitroso-N-acetylpenicillamine (an NO donor) AP-1 complex. In addition, Canals et al. (46) reported that significantly reduced RGC survival in a concentration- low concentrations of NO increased the number of TH dependent manner, whereas low concentrations increased immunoreactive cells and the TH protein levels in fetal RGC survival, particularly that of large RGCs, in vitro. midbrain cultures. These findings are supported by recent Thus, it has been suggested that, at low concentrations, NO studies which indicated that NO prevents NMDA-induced may be neuroprotective of retinal neuronal cells. reduction in the TH mRNA and TH protein levels in the In an in vivo system, we previously reported that 0.5 nmol retina (38). Whether NO regulates the TH expression at the of 1-hydroxy-2-oxo-3,3-bis (2-aminoethyl)-1-triazene (NOC transcriptional level in the retina remains to be elucidated; 18; an NO donor) significantly attenuated NMDA-induced however, it is suggested that low concentrations of NO may neurotoxicity in the rat retina (38). Conversely, Takahata et al. be neuroprotective of retinal dopaminergic cells. (39) reported that 1-hydroxy-2-oxo-3-(N-ethyl-2-aminoethyl)- 3-ethyl-1-triazene (NOC 12; an NO donor) induced dose- Possible role of dopamine in the retina dependent (over 200 nmol) retinal neurotoxicity. The half-life of NO release of NOC 18 is 21 h and that of NOC 12 is 100 Dopamine is a retinal neurotransmitter that regulates min (37ÆC, pH7.4). It has recently been reported that a short- several functions of various cells, including photoreceptors, lifetime NO donor, such as NOC 12, causes greater retinal horizontal cells, bipolar cells and ganglion cells (47). damage than a long-lifetime NO donor, NOC 18 (40). Dopaminergic receptors that mediate these actions of Therefore, the regulation of retinal neuronal cell survival by dopamine are generally classified into two groups, D1-like NO may be related not only to the NO concentration of the and D2-like receptors.
Load more

Recommended publications
  • Use of Computational Biochemistry for Elucidating Molecular Mechanisms of Nitric Oxide Synthase
    Use of Computational Biochemistry for Elucidating Molecular Mechanisms of Nitric Oxide Synthase Bignon, Emmanuelle; Rizza, Salvatore; Filomeni, Giuseppe; Papaleo, Elena Published in: Computational and Structural Biotechnology Journal DOI: 10.1016/j.csbj.2019.03.011 Publication date: 2019 Document version Publisher's PDF, also known as Version of record Citation for published version (APA): Bignon, E., Rizza, S., Filomeni, G., & Papaleo, E. (2019). Use of Computational Biochemistry for Elucidating Molecular Mechanisms of Nitric Oxide Synthase. Computational and Structural Biotechnology Journal, 17, 415- 429. https://doi.org/10.1016/j.csbj.2019.03.011 Download date: 02. Oct. 2021 Computational and Structural Biotechnology Journal 17 (2019) 415–429 Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/csbj Mini Review Use of Computational Biochemistry for Elucidating Molecular Mechanisms of Nitric Oxide Synthase Emmanuelle Bignon a,⁎, Salvatore Rizza b, Giuseppe Filomeni b,c, Elena Papaleo a,d,⁎⁎ a Computational Biology Laboratory, Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen, Denmark b Redox Signaling and Oxidative Stress Group, Cell Stress and Survival Unit, Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen, Denmark c Department of Biology, University of Rome Tor Vergata, Rome, Italy d Translational Disease Systems Biology, Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Protein Research University of Copenhagen, Copenhagen, Denmark article info abstract Article history: Nitric oxide (NO) is an essential signaling molecule in the regulation of multiple cellular processes. It is endoge- Received 21 December 2018 nously synthesized by NO synthase (NOS) as the product of L-arginine oxidation to L-citrulline, requiring NADPH, Received in revised form 17 March 2019 molecular oxygen, and a pterin cofactor.
    [Show full text]
  • Soluble Guanylate Cyclase B1-Subunit Expression Is Increased in Mononuclear Cells from Patients with Erectile Dysfunction
    International Journal of Impotence Research (2006) 18, 432–437 & 2006 Nature Publishing Group All rights reserved 0955-9930/06 $30.00 www.nature.com/ijir ORIGINAL ARTICLE Soluble guanylate cyclase b1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction PJ Mateos-Ca´ceres1, J Garcia-Cardoso2, L Lapuente1, JJ Zamorano-Leo´n1, D Sacrista´n1, TP de Prada1, J Calahorra2, C Macaya1, R Vela-Navarrete2 and AJ Lo´pez-Farre´1 1Cardiovascular Research Unit, Cardiovascular Institute, Hospital Clı´nico San Carlos, Madrid, Spain and 2Urology Department, Fundacio´n Jime´nez Diaz, Madrid, Spain The aim was to determine in circulating mononuclear cells from patients with erectile dysfunction (ED), the level of expression of endothelial nitric oxide synthase (eNOS), soluble guanylate cyclase (sGC) b1-subunit and phosphodiesterase type-V (PDE-V). Peripheral mononuclear cells from nine patients with ED of vascular origin and nine patients with ED of neurological origin were obtained. Fourteen age-matched volunteers with normal erectile function were used as control. Reduction in eNOS protein was observed in the mononuclear cells from patients with ED of vascular origin but not in those from neurological origin. Although sGC b1-subunit expression was increased in mononuclear cells from patients with ED, the sGC activity was reduced. However, only the patients with ED of vascular origin showed an increased expression of PDE-V. This work shows for the first time that, independently of the aetiology of ED, the expression of sGC b1-subunit was increased in circulating mononuclear cells; however, the expression of both eNOS and PDE-V was only modified in the circulating mononuclear cells from patients with ED of vascular origin.
    [Show full text]
  • Effects of Tetrahydrobiopterin on Endothelial Dysfunction in Rats with Ischemic Acute Renal Failure
    J Am Soc Nephrol 11: 301–309, 2000 Effects of Tetrahydrobiopterin on Endothelial Dysfunction in Rats with Ischemic Acute Renal Failure MASAO KAKOKI,* YASUNOBU HIRATA,* HIROSHI HAYAKAWA,* ETSU SUZUKI,* DAISUKE NAGATA,* AKIHIRO TOJO,* HIROAKI NISHIMATSU,* NOBUO NAKANISHI,‡ YOSHIYUKI HATTORI,§ KAZUYA KIKUCHI,† TETSUO NAGANO,† and MASAO OMATA* *The Second Department of Internal Medicine, Faculty of Medicine, and †Faculty of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan; ‡Department of Biochemistry, Meikai University School of Dentistry, Saitama, Japan; and §Department of Endocrinology, Dokkyo University School of Medicine, Tochigi, Japan. Abstract. The role of nitric oxide (NO) in ischemic renal injury 4 fmol/min per g kidney; serum creatinine: control 23 Ϯ 2, is still controversial. NO release was measured in rat kidneys ischemia 150 Ϯ 27, ischemia ϩ BH4 48 Ϯ 6 ␮M; mean Ϯ subjected to ischemia and reperfusion to determine whether SEM). Most of renal NOS activity was calcium-dependent, and (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4), a cofactor of NO its activity decreased in the ischemic kidney. However, it was synthase (NOS), reduces ischemic injury. Twenty-four hours restored by BH4 (control 5.0 Ϯ 0.9, ischemia 2.2 Ϯ 0.4, after bilateral renal arterial clamp for 45 min, acetylcholine- ischemia ϩ BH4 4.3 Ϯ 1.2 pmol/min per mg protein). Immu- induced vasorelaxation and NO release were reduced and renal noblot after low-temperature sodium dodecyl sulfate-polyac- excretory function was impaired in Wistar rats. Administration rylamide gel electrophoresis revealed that the dimeric form of of BH4 (20 mg/kg, by mouth) before clamping resulted in a endothelial NOS decreased in the ischemic kidney and that it marked improvement of those parameters (10Ϫ8 M acetylcho- was restored by BH4.
    [Show full text]
  • Nitric Oxide Synthase Inhibitors As Antidepressants
    Pharmaceuticals 2010, 3, 273-299; doi:10.3390/ph3010273 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review Nitric Oxide Synthase Inhibitors as Antidepressants Gregers Wegener 1,* and Vallo Volke 2 1 Centre for Psychiatric Research, University of Aarhus, Skovagervej 2, DK-8240 Risskov, Denmark 2 Department of Physiology, University of Tartu, Ravila 19, EE-70111 Tartu, Estonia; E-Mail: [email protected] (V.V.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +4577893524; Fax: +4577893549. Received: 10 November 2009; in revised form: 7 January 2010 / Accepted: 19 January 2010 / Published: 20 January 2010 Abstract: Affective and anxiety disorders are widely distributed disorders with severe social and economic effects. Evidence is emphatic that effective treatment helps to restore function and quality of life. Due to the action of most modern antidepressant drugs, serotonergic mechanisms have traditionally been suggested to play major roles in the pathophysiology of mood and stress-related disorders. However, a few clinical and several pre-clinical studies, strongly suggest involvement of the nitric oxide (NO) signaling pathway in these disorders. Moreover, several of the conventional neurotransmitters, including serotonin, glutamate and GABA, are intimately regulated by NO, and distinct classes of antidepressants have been found to modulate the hippocampal NO level in vivo. The NO system is therefore a potential target for antidepressant and anxiolytic drug action in acute therapy as well as in prophylaxis. This paper reviews the effect of drugs modulating NO synthesis in anxiety and depression. Keywords: nitric oxide; antidepressants; psychiatry; depression; anxiety 1. Introduction Recent data from Denmark and Europe [1,2], indicate that brain disorders account for 12% of all direct costs in the Danish health system and 9% of the total drug consumption was used for treatment of brain diseases.
    [Show full text]
  • Nitric Oxide Synthase Inhibitors
    Chapter 12 Nitric Oxide Synthase Inhibitors Elizabeth Igne Ferreira and Ricardo Augusto Massarico Serafim Additional information is available at the end of the chapter http://dx.doi.org/10.5772/67027 Abstract Nitric oxide (NO) is an endogenic product from plants, bacteria, and animal cells that has many important effects in those organisms. It is produced by nitric oxide synthase (NOS), which is found in main three isoforms, namely endothelial NOS (eNOS), induc- ible NOS (iNOS), and neuronal NOS (nNOS). It has an important role in homeostasis in different physiological systems, such as micro- and macro-vascularization, inhibition of platelet aggregation, and neurotransmission regulation in the central nervous, gastroin- testinal, respiratory, and genitourinary systems. However, its overproduction has been associated with diseases such as arthritis, asthma, cerebral ischemia, Parkinson’s disease, neurodegeneration, and seizures. For this reason, and due to better understanding of the molecular mechanisms by which NO provokes those diseases, the interest on the design of NOS inhibitors with therapeutic purposes has highly increased. Based on the forego - ing considerations, the proposal of this chapter is to show an overview about the design strategies, mechanism of action at the molecular level, and the main advances toward the search for selective NOS inhibitors available in the literature. Keywords: nitric oxide synthase isoforms, structure-based drug design, enzymatic inhibition, selectivity, heterocyclic compounds 1. Introduction Nitric oxide (NO) is a diatomic neutral molecule, produced by bacteria, plants, and animals. Having one unpaired electron, its effect in biological system is related to the stabilization of this electron. It acts as dissolved nonelectrolyte in the organisms, except for the lungs, where it is found in gaseous state [1–3].
    [Show full text]
  • 2-Thiouracil Is a Selective Inhibitor of Neuronal Nitric Oxide Synthase Antagonising Tetrahydrobiopterin-Dependent Enzyme Activation and Dimerisation
    FEBS 24297 FEBS Letters 485 (2000) 109^112 2-Thiouracil is a selective inhibitor of neuronal nitric oxide synthase antagonising tetrahydrobiopterin-dependent enzyme activation and dimerisation Anna Palumboa;*, Marco d'Ischiab, Fernando A. Cio¤c aZoological Station `Anton Dohrn', Villa Comunale, 80121 Naples, Italy bDepartment of Organic Chemistry and Biochemistry, University of Naples Federico II, Via Cinthia, 80134 Naples, Italy cDepartment of Neurosurgery, Second University of Naples, Viale Colli Aminei 21, 80100 Naples, Italy Received 11 October 2000; accepted 14 October 2000 First published online 6 November 2000 Edited by Barry Halliwell these enzymes in biological systems [6]. The research and clin- Abstract 2-Thiouracil (TU), an established antithyroid drug and melanoma-seeker, was found to selectively inhibit neuronal ical utility of this approach is well apparent in the case of neurological conditions, especially ischaemia/reperfusion and nitric oxide synthase (nNOS) in a competitive manner (Ki =20 WM), being inactive on the other NOS isoforms. The drug vasospasm secondary to subarachnoid haemorrhage, where apparently interfered with the substrate- and tetrahydrobiopterin recognition of the pathophysiological role of nNOS has war- (BH4)-binding to the enzyme. It caused a 60% inhibition of ranted considerable interest toward novel selective inhibitors H2O2 production in the absence of L-arginine and BH4, and of this isoform [7]. antagonised BH4-induced dimerisation of nNOS, but did not Functionally active nNOS is homodimeric and each subunit affect cytochrome c reduction. These results open new perspec- contains a reductase domain that binds NADPH, FAD and tives in the understanding of the antithyroid action of TU and FMN, and an oxygenase domain, that binds haem, the sub- provide a new lead structure for the development of selective strate L-arginine and tetrahydrobiopterin (BH ) [2,3].
    [Show full text]
  • Increased Arginase II Activity Contributes to Endothelial Dysfunction Through Endothelial Nitric Oxide Synthase Uncoupling in Aged Mice
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 44, No. 10, 594-602, October 2012 Increased arginase II activity contributes to endothelial dysfunction through endothelial nitric oxide synthase uncoupling in aged mice Woosung Shin1, Dan E. Berkowitz2,3 ArgII. These results might be associated with and Sungwoo Ryoo1,4 increased L-arginine bioavailability. Collectively, these results suggest that ArgII may be a valuable 1Department of Biology target in age-dependent vascular diseases. College of Natural Sciences Kangwon National University Keywords: aging; arginase II; endothelial nitric oxide Chuncheon 200-701, Korea synthase uncoupling; small interfering RNA; vascular 2Department of Anesthesiology and Critical Care Medicine diseases 3Department of Biomedical Engineering Johns Hopkins Medical Institutions Baltimore, MD 21287, USA Introduction 4Corresponding author: Tel, 82-33-250-8534; Fax, 82-33-251-3990; E-mail, [email protected] Cardiovascular disease is the leading cause of http://dx.doi.org/10.3858/emm.2012.44.10.068 morbidity and mortality in both industrialized and developing countries. Despite effective treatments Accepted 27 July 2012 for several established cardiovascular risk factors, Available Online 2 August 2012 such as hypertension and hypercholesterolemia, the incidence of cardiovascular disease is predicted Abbreviations: ABH, 2 (S)-amino-6-boronohexanoic acid; Ach, to increases as the population ages. Characteristic acetylcholine; Arg I, arginase I; ArgII, arginase II; DAF, 4-amino- events in the aging cardiovascular system include 5-methylamino-2', 7'-difluorescein; DHE, dihydroethidium; L-arg, vascular stiffness (Meaume et al., 2001), enhanced G L-arginine; L-NAME, L-N -nitroarginine methyl ester; MnTBAP, Mn reactive oxygen species (ROS) production (Finkel (III)tetrakis (4-benzoic acid) porphyrin chloride; ns, not significant; and Holbrook, 2000; Brandes et al., 2005), and ROS, reactive oxygen species; siArgII, siRNA to arginase II decreased nitric oxide (NO) bioavailability (Adler et al., 2003; Csiszar et al., 2008).
    [Show full text]
  • Novel Nitric Oxide Signaling Mechanisms Regulate the Erectile Response
    International Journal of Impotence Research (2004) 16, S15–S19 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Novel nitric oxide signaling mechanisms regulate the erectile response AL Burnett Department of Urology, The Johns Hopkins Hospital, Baltimore, Maryland, USA Nitric oxide (NO) is a physiologic signal essential to penile erection, and disorders that reduce NO synthesis or release in the erectile tissue are commonly associated with erectile dysfunction. NO synthase (NOS) catalyzes production of NO from L-arginine. While both constitutively expressed neuronal NOS (nNOS) and endothelial NOS (eNOS) isoforms mediate penile erection, nNOS is widely perceived to predominate in this role. Demonstration that blood-flow-dependent generation of NO involves phosphorylative activation of penile eNOS challenges conventional understanding of NO-dependent erectile mechanisms. Regulation of erectile function may not be mediated exclusively by neurally derived NO: Blood-flow-induced fluid shear stress in the penile vasculature stimulates phosphatidyl-inositol 3-kinase to phosphorylate protein kinase B, which in turn phosphorylates eNOS to generate NO. Thus, nNOS may initiate cavernosal tissue relaxation, while activated eNOS may facilitate attainment and maintenance of full erection. International Journal of Impotence Research (2004) 16, S15–S19. doi:10.1038/sj.ijir.3901209 Keywords: 1-phosphatidylinositol 3-kinase; penile erection; nitric-oxide synthase; endothelium Introduction synthesizes NO. In this brief review, the relatively new science of constitutive NOS activation via protein kinase phosphorylation is discussed, with The discovery of nitric oxide (NO) as a major particular attention given to its role in penile molecular regulator of penile erection about a erection and to its possible therapeutic relevance decade ago has had a profound impact on the field for ED.
    [Show full text]
  • Chronic Hypoxia Increases Inducible NOS-Derived Nitric Oxide in Fetal Guinea Pig Hearts
    0031-3998/09/6502-0188 Vol. 65, No. 2, 2009 PEDIATRIC RESEARCH Printed in U.S.A. Copyright © 2009 International Pediatric Research Foundation, Inc. Chronic Hypoxia Increases Inducible NOS-Derived Nitric Oxide in Fetal Guinea Pig Hearts LOREN THOMPSON, YAFENG DONG, AND LASHAUNA EVANS Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, Maryland 21201 ABSTRACT: Intrauterine hypoxia impacts fetal growth and organ ible NOS (iNOS)͔, all of which are expressed in the heart function. Inducible nitric oxide synthase (iNOS) and neuronal NOS (10,11). Specifically, eNOS is expressed constitutively in both (nNOS) expression was measured to assess the response of fetal endothelial cells and cardiomyocytes (10), nNOS in both hearts to hypoxic (HPX) stress. Pregnant guinea pigs were housed in cardiomyocytes and conducting tissue of cardiac ventricles a hypoxic chamber (10.5% O for 14 d, n ϭ 17) or room air 2 (12), and iNOS in cardiomyocytes (12) and in mature hearts [normoxic (NMX), n ϭ 17͔. Hearts of anesthetized near-term fetuses under conditions of hypoxia (12–14), heart failure (15), left were removed. mRNA ͓hypoxia-inducible factor, (HIF)-1␣,1␤,2␣, 3␣, iNOS, and nNOS͔ and protein levels (HIF-1␣, iNOS, and nNOS) ventricular hypertrophy (16) and cardiac cyanosis in children of fetal cardiac left ventricles were quantified by real time polymer- (17). NOS gene expression has been reported to be oxygen- ase chain reaction (PCR) and Western analysis, respectively. Cardiac sensitive, with levels varying among cardiac cells (18,19) and nitrite/nitrate levels were measured in the presence/absence of L-N6- endothelial cells of differing vascular origin (20–22).
    [Show full text]
  • International Journal of Impotence Research (1999) 11, Suppl 1, S65±S72 1 2
    International Journal of Impotence Research (1999) 11, Suppl 1, S65±S72 1 2 DOES CHANGE IN CARDIOVASCLL\R RISK FACTORS SERUM ANDROGENS :\ND ERECTILE DYSFUNCTION: PREVENT ERECTILE DYSFUNCTIO'.\? Carol A. Derby, Beth LONGITUDINAL DATA I R0\1 THI \:IASSACHUSETTS A. Mohr, Irwin Goldstein, Henry A. Feldman, Catherine B. MALE AGING STUDY. lknrv A. Idd1nan*, Christopher Johannes, John B. McKinlay (New Engbnd Research Institutes, Longcopet, and John B. I\IcKinlay' 1*Ncw England Research Watertown, MA 02742, USA). Inst., Watertown MA; tliniv ..\1a,s. \frd. Ctr., Worcester MA). Erectile dysfunction (ED) increases in prevalence with age, Although modifiable risk factors for erectile dysfunction (ED) but its relation to the slow decline in serum testosterone or other have been identified, little is known regarding prevention. We hormones controlling sexual function is uncertain, despite prospectively examined the association of changes in smoking reports of amelioration hy supplemental testosterone. In the (yes/ no), heavy alcohol use (>3 drinks /day), sedentary lifestyle Massachusetts Male Aging Study, a large population-hascd (< 200 kcal/day of moderate to intense activity) and obesity (BMI random sample of men aged 40-70 were twice interviewed at 2 2: 30 kg/m ) to incident ED in the randomly selected cohort of the home, in 1987-89 and 1995-97, on each occasion providing Massachusetts Male Aging Study. Of 1709 men aged 40-70 in comprehensive health information. blood samples, and a 1987-1989, analyses included 593 with follow-up in 1995-1997 privately completed sexual ,1c1i,itv LJUcstionnaire. We analyzed who were free of ED at baseline, had no history of prostate a subsample of 634 men vv hu had minimal or no ED at baseline cancer, and were not treated for heart disease or diabetes.
    [Show full text]
  • Nitric Oxide Therapy for Dermatologic Disease
    SPECIAL FOCUS y Nitric oxide-releasing materials Special Report For reprint orders, please contact [email protected] 0 Special Report2015/05/05 Nitric oxide therapy for dermatologic disease Brandon L Adler1 Future Sci. OA Nitric oxide (NO) plays an important role in the maintenance and regulation of the skin and the integrity of its environment. Derangement of NO production is implicated in & Adam J Friedman*,1,2,3 1 the etiology of a multitude of dermatologic diseases, indicating future therapeutic Department of Medicine (Division of Dermatology), Albert Einstein College of directions. In an era of increasing resistance rates to available antibiotics and subpar Medicine, Bronx, NY, USA development of new agents, NO is promising as a prospective topical broad-spectrum 2Department of Physiology & Biophysics, 1(1), FSO37 antimicrobial agent with small likelihood of resistance development. Because the Albert Einstein College of Medicine, greatest strides have been made in the setting of infectious disease and skin and soft- Bronx, NY, USA 3 tissue infection, this will be a major focus of this article. In addition, we will review George Washington School of Medicine & Health Sciences, Washington, DC, USA NO’s role in skin regulation and dysregulation, immune function, the various topical *Author for correspondence: release systems that have been devised and tested, NO’s relation to UV radiation and [email protected] skin pigmentation, and finally, its potential applications as a cosmeceutical. Nitric oxide (NO) is a molecule that plays many roles in both normal and abnormal skin processes. There is strong evidence that NO-releasing materials may serve as new, unique antimicrobial agents, at a juncture when current antibiotics are confounded by increasingly resistant microorganisms.
    [Show full text]
  • Tetrahydrobiopterin Restores Endothelial Function in Hypercholesterolemia
    Tetrahydrobiopterin Restores Endothelial Function in Hypercholesterolemia Erik Stroes,* John Kastelein,ʈ Francesco Cosentino,¶ Willem Erkelens,‡ Robert Wever,§ Hein Koomans,* Thomas Lüscher,¶ and Ton Rabelink* *Department of Nephrology, ‡Department of Internal Medicine, and §Department of Clinical Chemistry, University Hospital Utrecht, Utrecht, The Netherlands; ʈDepartment of Vascular Medicine, University Medical Center, Amsterdam, The Netherlands; and ¶Cardiovascular Research, University Hospital, Bern, Switzerland Abstract lium (1, 2). All major risk factors for atherosclerotic vascular disease, including hypercholesterolemia, have been associated In hypercholesterolemia, impaired nitric oxide activity has with impaired NO activity (3–8). The underlying defect in im- been associated with increased nitric oxide degradation by paired NO activity may involve both decreased formation (9) oxygen radicals. Deficiency of tetrahydrobiopterin, an essential as well as increased degradation of NO, by reaction with su- cofactor of nitric oxide synthase, causes both impaired nitric peroxide (10). Indeed, in several in vitro models increased oxide activity and increased oxygen radical formation. In this oxygen radical production has been demonstrated during hy- study we tested whether tetrahydrobiopterin deficiency con- percholesterolemia (11–13). It was proposed recently that en- tributes to the decreased nitric oxide activity observed in hanced oxygen radical production may be caused by nitric ox- hypercholesterolemic patients. Therefore, L-mono-methyl- ide synthase (NOS) itself. This is supported by observations arginine to inhibit basal nitric oxide activity, serotonin to showing that both deendothelialization (12) and infusion of stimulate nitric oxide activity, and nitroprusside as endothe- the selective NOS antagonist, nitro-l-arginine (13), could not lium-independent vasodilator were infused in the brachial only prevent NO formation, but could also inhibit increased artery of 13 patients with familial hypercholesterolemia and formation of oxygen radicals.
    [Show full text]